[EN] NOVEL TETRAHYDROQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS INÉDITS DE LA TÉTRAHYDROQUINOLINE
申请人:HOFFMANN LA ROCHE
公开号:WO2012101068A1
公开(公告)日:2012-08-02
A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein R1 to R8, A1 to A3 have the significance given in claim 1, can be used as AMPK modulators for treating obesity, hyperglycemia or type 2 diabetes.
The present invention relates to a compound of formula (I)
or a pharmaceutically acceptable salt or ester thereof, wherein R
1
to R
8
, A
1
to A
3
have the are as described herein and compositions including the compounds.
[EN] NOVEL TETRAHYDROQUINOLINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE TÉTRAHYDROQUINOLINE
申请人:HOFFMANN LA ROCHE
公开号:WO2012001020A1
公开(公告)日:2012-01-05
A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein A1 to A3 and R1 to R10 have the significance given in claim 1, can be used as AMPK activators.
A compound of formula (I)
or a pharmaceutically acceptable salt or ester thereof, wherein A
1
to A
3
and R
1
to R
10
have the significance given in claim
1
, can be used as a medicament. These compounds are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes and cancers.